Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Aug 9;14(8):991.
doi: 10.3390/life14080991.

Chemotherapy-Induced Peripheral Neuropathy: A Recent Update on Pathophysiology and Treatment

Marina Mattar  1 , Florence Umutoni  2 , Marwa A Hassan  1 , M Wambui Wamburu  3 , Reagan Turner  4 , James S Patton  2 , Xin Chen  5 , Wei Lei  1   2
Affiliations
Review

Chemotherapy-Induced Peripheral Neuropathy: A Recent Update on Pathophysiology and Treatment

Marina Mattar et al. Life (Basel). .

Abstract

Chemotherapy-induced peripheral neuropathy (CIPN) is a major long-lasting side effect of some chemotherapy drugs, which threatens cancer survival rate. CIPN mostly affects sensory neurons and occasionally motor neurons, causing numbness, tingling, discomfort, and burning pain in the upper and lower extremities. The pathophysiology of CIPN is not completely understood; however, it is believed that chemotherapies induce peripheral neuropathy via directly damaging mitochondria, impairing the function of ion channels, triggering immunological mechanisms, and disrupting microtubules. The treatment of CIPN is a medical challenge, and there are no approved pharmacological options. Currently, duloxetine and other antidepressants, antioxidant, anti-inflammatory, and ion-channel targeted therapies are commonly used in clinics to relieve the symptoms of CIPN. Several other types of drugs, such as cannabinoids, sigma-1 receptor antagonists, and nicotinamides ribose, are being evaluated in preclinical and clinical studies. This paper summarizes the information related to the physiology of CIPN and medicines that could be used for treating this condition.

Keywords: cannabinoid; chemotherapy-induced peripheral neuropathy; duloxetine; pain; pathophysiology.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

References

    1. Zajączkowska R., Kocot-Kępska M., Leppert W., Wrzosek A., Mika J., Wordliczek J. Mechanisms of Chemotherapy-Induced Peripheral Neuropathy. Int. J. Mol. Sci. 2019;20:1451. doi: 10.3390/ijms20061451. - DOI - PMC - PubMed
    1. Ibrahim E.Y., Ehrlich B.E. Prevention of chemotherapy-induced peripheral neuropathy: A review of recent findings. Crit. Rev. Oncol. Hematol. 2020;145:102831. doi: 10.1016/j.critrevonc.2019.102831. - DOI - PMC - PubMed
    1. Molassiotis A., Cheng H.L., Leung K.T., Li Y.C., Wong K.H., Au J.S.K., Sundar R., Chan A., Ng T.R., Suen L.K.P., et al. Risk factors for chemotherapy-induced peripheral neuropathy in patients receiving taxane- and platinum-based chemotherapy. Brain Behav. 2019;9:e01312. doi: 10.1002/brb3.1312. - DOI - PMC - PubMed
    1. Gordon-Williams R., Farquhar-Smith P. Recent advances in understanding chemotherapy-induced peripheral neuropathy. F1000Research. 2020;9 doi: 10.12688/f1000research.21625.1. - DOI - PMC - PubMed
    1. Seretny M., Currie G.L., Sena E.S., Ramnarine S., Grant R., MacLeod M.R., Colvin L.A., Fallon M. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis. Pain. 2014;155:2461–2470. doi: 10.1016/j.pain.2014.09.020. - DOI - PubMed

LinkOut - more resources